Empagliflozin Perception Mapping Survey
Indian physicians demonstrate strong awareness and largely guideline-concordant prescribing attitudes toward empagliflozin in T2DM with cardiovascular or renal complications. Nevertheless, under-recognition of asymptomatic HF and variability in CKD management highlight the need for targeted education and policy initiatives to further strengthen evidence-based practice.
Authors
- Jothydev Kesavadev (ORCID: https://orcid.org/0000-0001-6522-6391)
- Vijay Panikar
- DHARMEN H. PUNATAR
- Aravinda Jagadeesha
- Ketan Mehta
- Arun Kumar Kedia (ORCID: https://orcid.org/0000-0003-4232-7442)
- Snehal Tanna
- Sanhita R Walawalkar
- Lotika Purohit
- Ami Sanghvi
- Rajiv Kovil (ORCID: https://orcid.org/0000-0003-1273-9497)
- Mukund R. Patel (ORCID: https://orcid.org/0000-0002-3117-5095)
- Garima Mathur (ORCID: https://orcid.org/0000-0001-5216-4849)
- Sameer Muchhala
- Kamlesh Nayak
- Vishal Gala
- Anil Kumar Virmani (ORCID: https://orcid.org/0000-0003-4964-9102)
- Sameer Chandratre
- Akanksha Sonkar
Institutions
- Indira Gandhi Agricultural University (IN)
- Diabetes Australia (AU)
- Lilavati Hospital & Research Centre (IN)
- Indra (Spain) (ES)
- Diabetes Care and Research Foundation (IN)
- Vedic Lifesciences (India) (IN)
- Jupiter Medical Center (US)
- Bangalore Diabetes Centre (IN)
- Diabetes Care & Hormone Clinic (IN)
- Zydus Lifesciences Limited (India) (IN)
- Jothydev's Diabetes and Research Center (IN)
- Indravati Hospital & Research Centre (IN)
- Pulmonary Associates (US)
- Dr. Kovil's Diabetes Care Centre (IN)
Publication Details
- Journal
- Cureus
- Published
- 2025-12-12
- DOI
- https://doi.org/10.7759/cureus.99024
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00